V
Variantyx
Providing comprehensive genetic testing using a single method approach that is based on whole genome sequencing
About Variantyx
Variantyx is a technology-driven molecular diagnostics company focused on precision medicine. The company provides advanced genomic testing solutions to aid in the diagnosis of rare genetic disorders, as well as for the reproductive health and precision oncology markets.
Read full description
Its core business revolves around proprietary whole-genome sequencing and analysis platforms. These platforms are designed to deliver comprehensive genetic insights from a single test, which helps clinicians in diagnosing diseases and formulating personalized treatment plans. The company serves healthcare providers, hospitals, and other clinical settings that require detailed genetic diagnostics.
Variantyx operates in the healthcare and biotechnology sectors, specifically within the molecular diagnostics market. Its business model is based on providing fee-for-service genomic testing. Revenue is generated by billing for the various tests performed, with options for insurance claims and self-pay, targeting a client base that includes patients needing diagnostic services for genetic conditions, prenatal screening, or cancer treatment.
At a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Herzliya, Israel
- Employees
- 224
- Open positions
- 10
- Dealroom signal
- 87.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Personal Health, Testing, Biotechnology, DNA, Genetics and genomics, Non-Invasive medical devices and treatments, Health Diagnostics, Spinout, Biotech and Pharma, medical testing
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Apr 2024 | $36M | $144M | Pitango Venture Capital · Peregrine Ventures · New Era Capital Partners · Bosch Ventures | ↗ |
| LATE VCOther financing | Oct 2023 | $0 | — | Pitango Venture Capital · Bosch Ventures · Peregrine Ventures · 20/20 HealthCare Partners | ↗ |
Growth signals
Latest recorded traffic for Variantyx is 11K monthly website visits, up 10% over the last three months. Variantyx's team grew 0.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later8 investors entered at this stage
20/20 HealthCare Partners- GFGHS Fund
IBM Ventures
New Era Capital Partners
Bosch Ventures
New Era Capital
Peregrine Ventures
Kreos Capital
Other known investors1 additional known investor
Tel Aviv University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Variantyx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Variantyx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.